XML 28 R13.htm IDEA: XBRL DOCUMENT v3.25.2
STOCKHOLDERS' EQUITY
12 Months Ended
Jun. 30, 2025
STOCKHOLDERS' EQUITY  
STOCKHOLDERS' EQUITY

5. STOCKHOLDERS’ EQUITY

On December 8, 2021, our board of directors authorized the amended and restated Certificate of Incorporation which increased the total authorized shares of common stock from 50,000,000 to 60,000,000 shares. As of June 30, 2025 and 2024, the Company had 33,237,000 and 32,698,000 shares of common stock issued, respectively, and 27,083,000 and 29,160,000 shares of common stock outstanding, respectively.

Common Stock

We have reserved shares of common stock for issuance as of June 30, 2025 as follows:

    

Common

Stock

Reserves

Stock options outstanding

 

3,954,716

Restricted stock units outstanding

 

179,155

Stock available for future grants or issuance:

 

2005 Stock Incentive Plan

2,089,443

2017 Employee Stock Purchase Plan

589,695

Total reserved shares of common stock for issuance

 

6,813,009

Preferred Stock

We are authorized to issue 5,000,000 shares of preferred stock with a par value of $0.001 per share. As of June 30, 2025 and 2024, no shares of preferred stock are issued or outstanding. Our board of directors has the authority, without further action by our stockholders, to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of the common stock.

Stock-Based Compensation

We account for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. Under the fair value recognition provisions of ASC 718, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period, net of expected forfeitures. Stock-based compensation expense consists of expenses for stock options, RSUs, and discounted employee common stock granted under our 2017 Employee Stock Purchase Plan (ESPP).

2005 Management Stock Option Plan

In May 2005, our board of directors adopted the 2005 Management Stock Option Plan (2005 Management Plan) which provides for the grant of non-statutory stock options to directors, officers and key employees of eGain and its subsidiaries. The expiration date of the 2005 Management Plan was September 30, 2024. Options under the 2005 Management Plan are granted at a price not less than 100% of the fair market value of the common stock on the date of grant. Options granted under the 2005 Management Plan are subject to eGain’s right of repurchase, whose right shall lapse with respect to one-forty-eighth (1/48th) of the shares granted to a director, officer or key employee for each month of continuous service provided by such director, officer or key employee to eGain. The options granted under this plan are exercisable for up to ten years from the date of grant.

The following table represents the activity under the 2005 Management Plan:

    

Shares

    

    

Weighted

Available for

Options

Average

Grant

Outstanding

Exercise Price

Balance as of June 30, 2023

 

71,983

826,717

$

3.29

Options Exercised

 

(114,200)

$

4.16

Balance as of June 30, 2024

 

71,983

712,517

$

3.15

Options Exercised

(134,000)

$

3.12

Options Forfeited / Expired

101,000

(101,000)

$

6.28

Plan Shares Expired

(172,983)

Balance as of June 30, 2025

477,517

$

2.49

2005 Stock Incentive Plan

In March 2005, our board of directors adopted the 2005 Stock Incentive Plan which provides for the grant of stock options and RSUs to eGain’s employees, officers, directors and consultants. Our board extended the expiration date of the 2005 Stock Incentive Plan to October 11, 2033 and made certain other changes. Options granted under the 2005 Stock Incentive Plan are non-qualified stock options. Non-qualified stock options may be granted to employees with exercise prices of no less than the fair value of the common stock on the date of grant. The options generally vest ratably over a period of four years and expire no later than ten years from the date of grant. RSUs granted under the 2005 Stock Incentive Plan contain service-based condition and is valued at the grant date fair value; our closing stock price on the date of grant. The RSUs generally vest ratably over a period of one year.

The following table represents the activity under the 2005 Stock Incentive Plan:

    

Shares

    

    

Weighted

Available for

Options

Average

Grant

Outstanding

Exercise Price

Balance as of June 30, 2023

 

1,057,983

4,059,282

$

10.06

Options Granted

 

(120,300)

120,300

$

6.47

Options Exercised

 

(145,293)

$

2.66

Options Forfeited / Expired

 

319,795

(319,795)

$

9.92

RSUs Granted

(200,821)

$

RSUs Forfeited

15,394

$

Balance as of June 30, 2024

 

1,072,051

3,714,494

$

10.24

Shares Added

1,000,000

$

Options Granted

(654,467)

654,467

$

5.57

Options Exercised

(57,000)

$

2.78

Options Forfeited / Expired

834,762

(834,762)

$

9.48

RSUs Granted

(226,654)

$

RSUs Forfeited

63,751

$

Balance as of June 30, 2025

2,089,443

3,477,199

$

9.67

During the fiscal year ended June 30, 2025, we granted zero stock options to consultants.

A summary of RSU activity during the year ended June 30, 2025 is as follows:

Weighted Average

Grant Date

Shares

Fair Value per Share

Non-vested RSUs as of June 30, 2024

 

185,427

$

7.55

RSUs granted

 

226,654

$

5.71

RSUs released

 

(169,175)

$

7.54

RSUs forfeited

 

(63,751)

$

6.20

Non-vested RSUs as of June 30, 2025

 

179,155

$

5.71

We granted 2,659 and 3,901 RSUs to consultants during fiscal year ended June 30, 2025 and 2024, respectively.

The following table summarizes information about stock options outstanding and exercisable under all stock option plans as of June 30, 2025:

Options Outstanding

Options Exercisable

Weighted

Range of

Average

Weighted

Weighted

Exercise

Number of

Remaining

Average

Number of

Average

Prices

    

Shares

    

Contractual Life

    

Exercise Price

    

Shares

    

Exercise Price

$1.80

12,700

1.66

$

1.80

12,700

$

1.80

$2.50

547,929

2.15

$

2.50

547,929

$

2.50

$3.40-$5.71

496,934

7.83

$

4.93

133,809

$

4.02

$5.73-$7.96

424,940

7.12

$

6.94

191,029

$

7.55

$8.20-$11.23

295,951

4.54

$

10.07

271,708

$

10.10

$11.36

1,970,656

5.80

$

11.36

1,853,377

$

11.36

$11.47-$12.45

126,656

4.75

$

11.98

117,151

$

11.99

$13.75

65,400

3.04

$

13.75

65,400

$

13.75

$14.40

3,550

1.58

$

14.40

3,550

$

14.40

$19.11

10,000

5.29

$

19.11

10,000

$

19.11

$1.80-$19.11

3,954,716

5.50

$

8.80

3,206,653

$

9.27

The summary of options vested and exercisable as of June 30, 2025 comprised:

    

    

    

Weighted

Average

Weighted

Aggregate

Remaining

Number of

Average

Intrinsic

Contractual

Shares

Exercise Price

Value

Term

Options outstanding

    

3,954,716

$

8.80

$

2,783,577

5.50

Options fully vested and expected to vest

 

3,849,106

$

8.88

$

2,715,828

5.39

Options exercisable

 

3,206,653

$

9.27

$

2,410,823

4.74

The aggregate intrinsic value in the preceding table represents the total intrinsic value based on stock options with a weighted average exercise price less than our closing stock price of $6.25 as of June 30, 2025 that would have been received by the option holders, had they exercised their options on June 30, 2025. The total intrinsic value of stock options exercised was $501,000 and $806,000 during fiscal years 2025 and 2024, respectively.

2017 Employee Stock Purchase Plan

In October 2017, our board of directors adopted the ESPP which provided eligible employees the option purchase the Company’s common stock through payroll deductions at a price equal to 85% of the lower of the fair market value at the entry date of the applicable offering period or at the end of each applicable purchasing period. The offering period, meaning

a period with respect to which the right to purchase shares of our common stock may be granted under the ESPP, will not exceed twenty-seven months and consist of a series of six-month purchase periods. Eligible employees may join the ESPP at the beginning of any six-month purchase period. Under the terms of the ESPP, employees can choose to have between 1% and 15% of their base earnings withheld to purchase the Company’s common stock. On December 17, 2021, our board of directors authorized an additional 600,000 shares of common stock to be available for issuance under ESPP. As of June 30, 2025, 589,695 shares of common stock were reserved for future issuance under the ESPP.

Valuation of Stock-based Awards

Determining the fair value of the stock options and ESPP awards at the grant date requires significant judgment and the use of estimates, particularly surrounding Black-Scholes valuation assumptions such as stock price volatility and expected option term.

The table below summarizes the effect of stock-based compensation (in thousands):

Fiscal Year Ended June 30,

    

2025

    

2024

Stock-based compensation expense

$

(2,449)

$

(4,529)

Income tax expense

 

(62)

 

(97)

Net income effect

$

(2,511)

$

(4,626)

The Company recognized $62,000 and $97,000 of tax expense related to stock-based compensation expense for eGain UK and Exony for the fiscal years ended June 30, 2025 and 2024, respectively. There is no income tax effect that has been recognized relating to the stock-based compensation expense in the US due to full valuation allowance.

Total stock-based compensation to non-employee awards were expense of $37,000 and $23,000 during the fiscal years ended June 30, 2025 and 2024, respectively. A net reversal of stock-based compensation reflects the forfeiture of unvested stock awards due to termination of service.

  

We utilized the Black-Scholes valuation model for estimating the fair value of the stock-based compensation of options and ESPP stock purchase rights. All shares of our common stock issued pursuant to our stock plans are only issued out of an authorized reserve of shares of common stock, which were previously registered with the Securities and Exchange Commission on a registration statement on Form S-8.

During the fiscal years ended June 30, 2025 and 2024, there were 654,467 and 120,300 options granted, respectively, with a weighted average grant date fair value of $2.65 and $3.16, per share, respectively.

We used the following assumptions as inputs into the Black-Scholes valuation model to estimate the fair value of the options granted:

Fiscal Year Ended June 30,

    

2025

2024

Dividend yield

 

Expected volatility

 

53

%  

54

%  

Average risk-free interest rate

 

4.11

%  

4.39

%  

Expected life (in years)

 

4.55

4.56

We used the following assumptions as inputs into the Black-Scholes valuation model to estimate the fair value of the ESPP stock purchase right:

Fiscal Year Ended June 30,

2025

2024

Dividend yield

Expected volatility

57

%  

57

%

Average risk-free interest rate

2.48

%  

2.16

%  

Expected term (in years)

0.50

0.50

During the fiscal years ended June 30, 2025 and 2024, employees were granted the right and purchased an aggregate of 178,602 and 170,106 shares, respectively, with a weighted average grant date fair value of $1.74 and $2.14, per share, respectively, pursuant to the ESPP. Total stock-based compensation expense related to those purchase rights was $303,000 and $362,000 for the fiscal years ended June 30, 2025 and 2024, respectively.

The dividend yield of zero is based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends. We determined the appropriate measure of expected volatility by reviewing historic volatility in the share price of our common stock, as adjusted for certain events that management deemed to be non-recurring and non-indicative of future events. The risk-free interest rate is derived from the average U.S. Treasury Strips rate.

We base our estimate of expected life of a stock option on the historical exercise behavior, and cancellations of all past option grants made by the Company during the time period which its common stock has been publicly traded, the contractual term of the option, the vesting period and the expected remaining term of the outstanding options.

In accordance with Accounting Standards Updates (ASU) 2016-09, Compensation—Stock Compensation: Improvements to Employee Share-Based Accounting, we elected to continue to estimate forfeitures in the calculation of stock-based compensation expense.

The following table summarizes stock-based compensation expense relating to stock options for the years ended June 30, 2025 and 2024, respectively (in thousands):

Fiscal Year Ended June 30,

2025

2024

Cost of revenue

$

343

$

831

Research and development

183

1,043

Sales and marketing

154

436

General and administrative

433

1,038

Total

$

1,113

$

3,348

Total unamortized compensation cost, net of forfeitures, for all options granted but not yet vested as of June 30, 2025 was $867,000 which is expected to be recognized over the weighted average period of 1.23 years.

The following table summarizes stock-based compensation expense relating to RSUs for the years ended June 30, 2025 and 2024, respectively (in thousands):

Fiscal Year Ended June 30,

2025

2024

Cost of revenue

$

411

$

287

Research and development

350

260

Sales and marketing

152

147

General and administrative

120

125

Total

$

1,033

$

819

Total unamortized compensation cost, net of forfeitures, for all RSUs granted but not yet vested as of June 30, 2025 was $393,000, which is expected to be recognized over the weighted average period of 0.38 years.

The following table summarizes stock-based compensation expense relating to the ESPP for the years ended June 30, 2025

and 2024, respectively (in thousands):

Fiscal Year Ended June 30,

2025

2024

Cost of revenue

$

98

$

119

Research and development

120

120

Sales and marketing

46

62

General and administrative

39

61

Total

$

303

$

362

Total unamortized compensation cost, net of forfeitures, for all purchase rights related to ESPP granted but not yet vested as of June 30, 2025 was $116,000, which is expected to be recognized over a weighted average period of  0.42 years.